Akebia Therapeutics Inc. (AKBA)
AKBA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1517022/000151702226000020/0001517022-26-000020-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | AKBA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001517022 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $236.2M |
| Net income | -$5.3M |
| Operating income | $23.5M |
| Net margin | -2.3% |
| Operating margin | 9.9% |
| Revenue growth | +47.5% |
| Cash | $184.8M |
| Total assets | $376.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.5× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $159.3M cash; operating cash flow $3.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 277,663,875 (2026-11-02); 265,365,993 a year earlier; 188,389,415 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-10-23 |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-10 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $87K, sold $963K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $36.9M | -$14.4M | $2.3M | $159.3M | $50.3M | $197.2M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $49.1M | -$8.9M | $3.5M | $155.5M | $49.6M | $219.1M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $53.5M | -$9.1M | -$21.2M | $162.6M | $48.9M | $232.4M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $57.6M | -$12.2M | $31.1M | $184.8M | $48.3M | $236.2M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $58.8M | $540K | $28.1M | $166.4M | $47.6M | $225.1M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $62.5M | $247K | $22.3M | $137.3M | $47.1M | $203.7M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $57.3M | $6.1M | -$13.6M | $113.4M | $46.5M | $184.9M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $46.5M | -$22.8M | -$4.5M | $51.9M | $38.7M | $160.2M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-03-20 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 887 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +18.2% |
| 1 month | -38.4% |
| 3 months | -45.5% |
| Year to date | -70.6% |
| 1 year | -73.1% |
| From 52-week high | -73.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ALXO | ALX Oncology Holdings Inc. | $1.00 | -3.85% | $124.9M |
| SPRB | Spruce Biosciences Inc. | $42.25 | -2.45% | $121.4M |
| CNTN | Canton Strategic Holdings Inc. | $1.64 | -4.09% | $130.7M |
| NTHI | NeOnc Technologies Holdings Inc. | $4.54 | -7.54% | $131.0M |
| UPB | Upstream Bio Inc. | $2.15 | -22.66% | $117.8M |
| MENS | Jyong Biotech Ltd. | $1.77 | +0.57% | $134.6M |
| IMUX | Immunic Inc. | $7.23 | -3.86% | $114.8M |
| PDSB | PDS Biotechnology Corporation | $0.9241 | +5.90% | $113.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier